Clarityne has no clinically significant sedative properties at the daily recommended dose of 10 mg.
Most commonly reported adverse effects include fatigue, headache, somnolence, dry mouth, gastrointestinal disorders eg, nausea, gastritis, and also allergic symptoms eg, rash.
During the marketing of Clarityne tablet, alopecia, anaphylaxis and abnormal hepatic function have been reported rarely.
Similarly, the incidence of adverse effects associated with Clarityne syrup has been comparable to that of placebo. In controlled pediatric clinical trials, the incidence of treatment-related headache, sedation and nervousness, which were rarely reported events, was similar to that of placebo.